peptide t tfa

Peptide T (TFA), an octapeptide derived from the V2 region of HIV-1 gp120, functions as a ligand for the CD4 receptor, thereby effectively inhibiting HIV binding to the CD4 receptor.

ADWX 1 TFA is a novel peptide that potently targets and inhibits the Kv1.3 channel, with an IC50 of 1.89 pM. It specifically suppresses the activity of the Kv1.3 channel, in addition to inhibiting initial calcium signaling and NF-κB activation. This compound has been shown to ameliorate symptoms in rats with experimental autoimmune encephalomyelitis (EAE). ADWX 1 TFA is utilized in research focused on T-cell-mediated autoimmune diseases.

Fmoc-Thr(tBu)-OH is a threonine derivative commonly used in Fmoc-based solid-phase peptide synthesis, with the t-butyl side-chain protecting group removable under TFA treatment while remaining stable during cleavage from Wang or Rink amide resins, allowing controlled peptide assembly.

Acyline TFA, a gonadotropin-releasing hormone (GnRH) peptide analogue, functions as a GnRH antagonist, effectively suppressing gonadotropin and testosterone (T) levels [1].

LCMV gp33-41 (TFA), an 11-amino-acid carboxyl-extended peptide, comprises a lymphocytic choriomeningitis virus sequence that is presented by MHC class I H-2Db molecules to cytotoxic T lymphocytes [1].

CD31 TFA, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), functions as the specific receptor for Clostridium perfringens beta-Toxin (CPB) in endothelial cells. It is recognized as an ER-MP12 antigen and plays a pivotal role in connecting mechanical stress, metabolism, and inflammation. Additionally, the CD31 TFA peptide facilitates the phosphorylation of CD31 ITIM 686 and SHP2, further inhibiting TCR-induced T-cell activation [1]-[5].

Myelin Basic Protein (87-99) TFA, an encephalitogenic peptide, promotes basic protein-specific T cell proliferation and induces Th1 polarization in peripheral blood mononuclear cells, contributing to the pathogenesis of multiple sclerosis (MS) [1] [2].

ELAAWCRWGFLLALLPPGIAG TFA (P5), a 21-amino-acid peptide (aa 5-25) originating from the rat HER2/neu protein, has been shown to elicit cytotoxic T lymphocyte (CTL) responses in mice with HER2-positive tumors [1].

Caerin 1.1 TFA, a host defense peptide derived from the Australian tree frog Litoria's glandular secretions, exhibits anti-proliferative effects on HeLa cells and induces apoptosis. Additionally, it has the potential to augment adaptive T cell immune responses [1].

MOG (35-55) TFA is a minor component of central nervous system myelin with encephalitogenic activity. It can induce T cell proliferation, activate Th1 cytokine responses, and elicit high levels of IgG antibodies, leading to relapsing-remitting central nervous system disease characterized by extensive plaque-like demyelination. It is commonly used to induce experimental autoimmune encephalomyelitis (EAE) models.

SIIVFEKL TFA is a variant of the principal MHC class I-restricted epitope, SIINFEKL. This antigenic peptide stimulates specific T cells in experimental settings to study competitive interactions among T cells. SIIVFEKL TFA exhibits lower affinity for the OT-I T cell receptor (TCR) and can be utilized to detect CD8+ T cells.

SIYNFEKL TFA, a variant of the primary MHC class I-restricted epitope SIINFEKL, serves as an antigenic peptide for stimulating specific T cells in experimental settings to study competitive interactions among T cells. It exhibits lower affinity for the OT-I T cell receptor (TCR), making it useful for detecting CD8+ T cells.

NY-ESO-1 (157-165) peptide (TFA) is a peptide derived from the NY-ESO-1 protein. This peptide can activate the immune system and is specifically recognized by CD8+ T cells in HLA-A2 positive individuals, thereby initiating an immune response. It is expressed in various tumors and can serve as a target for tumor immunotherapy.

Tetanus Toxin (830–844) TFA is a bioactive peptide. It acts as a CD4+ T cell epitope derived from tetanus toxin (TT830–844). This hybrid CD4+ T cell epitope binds to various HLA-DRB molecules, potentially activating CD4+ T cell responses in a broad population.

Hyaluronan-binding peptide, biotin labeled TFA, is a bioactive peptide. (This peptide is biotinylated through a C-terminal GGGSK spacer and binds to hyaluronan. Hyaluronan (HA) is a non-sulfated glycosaminoglycan found in the extracellular matrix and on cell surfaces. It plays a significant role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte transport to inflamed tissues, and cancer metastasis. This peptide has been demonstrated to block the interaction between HA and CD44 receptors and inhibit T-cell proliferation.)

Vm24-toxin (Vaejovis mexicanus peptide 24) TFA is a peptide composed of 36 amino acids, known for effectively and selectively blocking Kv1.3 channels, exhibiting an affinity (Kd) of approximately 3 pM in lymphocytes. It demonstrates over 1500 times greater affinity for Kv1.3 compared to other tested potassium channels. The structure of Vm24-toxin TFA includes a twisted cystine-stabilized α/β motif, comprising a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Additionally, Vm24-toxin TFA can attenuate the response of CD4+ effector memory T cells to T-cell receptor (TCR) stimulation.

PD-L1 inhibitory peptide TFA is an inhibitory peptide targeting programmed cell death ligand 1 (PD-L1). It binds to PD-L1, lifting immune suppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA shows potential for use in cancer research.

EBVBZLF1 (190-197) TFA is an immunodominant CEF control peptide derived from the Epstein-Barr virus (EBV). It serves as an optimal epitope for CD8+ T cells, facilitating the release of IFNg. The CD8 positive cytotoxic T lymphocyte (CTL) response elicited by EBVBZLF1 (190-197) TFA is diverse and capable of cross-recognizing similar peptide segments from both host proteins and bacterial proteins. This compound is useful for research in autoimmune diseases.

AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.

ANT308 TFA serves as an antagonist for the vasoactive intestinal peptide (VIP receptor). It significantly enhances the activation and proliferation of T cells. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 TFA impedes the migration and metastasis of melanoma cells and induces apoptosis. This compound is applicable in research related to acute myeloid leukemia (AML) and uveal melanoma (UVM).